Belgian sunshine rules – Submissions required by 31 May 2018 at the latest

On 27 December 2016, the Belgian Law of 18 December 2016 concerning various health-related matters (“the Sunshine Act”) was adopted by the Belgian Ministry for Public Health. The Sunshine Act provides that life sciences companies must publically disclose information concerning all pecuniary advantages or benefits in kind granted, directly or indirectly from Belgium or elsewhere, to a number of defined beneficiaries. These include health care professionals or health care professional organisations established in Belgium.

The information concerning transfers of value must be published annually on a website accessible by the public ( and at the latest on 31 May of the year after the relevant reporting period. For the transfers of value which occurred in 2017, the deadline is therefore, on Thursday 31 May 2018.

Medical devices and pharmaceutical companies must also ensure compliance with their data protection obligations and inform relevant beneficiaries including health care professionals that they are processing their personal data for the purpose of the Belgian sunshine rules. Such information must comply with the General Data Protection Regulation (GDPR) which will apply from 25 May 2018.

Please contact our team should you have any question concerning the Belgian Sunshine Act and the GDPR.


Authored by Fabien Roy

Fabien Roy


This website is operated by Hogan Lovells Solutions Limited, whose registered office is at 21 Holborn Viaduct, London, United Kingdom, EC1A 2DY. Hogan Lovells Solutions Limited is a wholly-owned subsidiary of Hogan Lovells International LLP but is not itself a law firm. For further details of Hogan Lovells Solutions Limited and the international legal practice that comprises Hogan Lovells International LLP, Hogan Lovells US LLP and their affiliated businesses ("Hogan Lovells"), please see our Legal Notices page. © 2021 Hogan Lovells.

Attorney advertising. Prior results do not guarantee a similar outcome.